A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis.

Abstract	A 12-week trial was carried out to compare the efficacy of pirazolac (300-600 mg b.i.d.) with that of indomethacin (25-50 mg t.i.d.) in patients with ankylosing spondylitis. A total of 119 patients completed the treatment period, with 32 drop-outs. Both therapies showed significant improvements in clinical symptoms.
Authors	C Carcassi, G La Nasa, G Perpignano
Journal	Drugs under experimental and clinical research (Drugs Exp Clin Res) Vol. 16 Issue 1 Pg. 29-37 ( 1990) ISSN: 0378-6501 [Print] Switzerland
PMID	2198157 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References	Anti-Inflammatory Agents, Non-Steroidal Pyrazoles pirazolac Indomethacin
Topics	Administration, Oral Adolescent Adult Aged Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects, therapeutic use) Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Drug Tolerance Female Humans Indomethacin (administration & dosage, adverse effects, therapeutic use) Male Middle Aged Multicenter Studies as Topic Pyrazoles (administration & dosage, adverse effects, therapeutic use) Randomized Controlled Trials as Topic Spondylitis, Ankylosing (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!